Literature DB >> 3228143

Prenatal detection of 46,XY,rec(5),dup q, inv(5)(p13q33) using DNA analysis, flow cytometry, and in situ hybridization to supplement classical cytogenetic analysis.

A O Martin1, H Northrup, D H Ledbetter, B Trask, G van den Engh, M M Le Beau, A L Beaudet, J W Gray, G Sekhon, N Krassikoff.   

Abstract

Distinguishing between balanced and unbalanced chromosome complements segregating from parental rearrangements may be difficult using only classical cytogenetic techniques if banding morphology is similar under both expectations. In these situations, supplementing cytogenetic analysis with molecular genetic techniques and flow cytometry may provide increased diagnostic accuracy. To illustrate this, we present a case in which similar band pattern morphology would be expected for both the balanced carrier (heterozygote) and the recombinant dup q chromosome complements segregating from a mother with a balanced inversion [46,XX,inv(5)(p13q33)]. The parents came to Northwestern for consultation after receiving conflicting interpretations of their first amniotic fluid cultures. An ultrasound examination was said to be normal. They inquired whether there were ways to increase their confidence that the complement was unbalanced. Their reluctance to terminate the pregnancy was due to a 6-year history of infertility. After extensive counselling, the couple elected repeat amniocentesis. Further cytogenetic analysis of repeat amniotic fluid cultures by G-banding and R-banding, molecular genetic analysis with highly polymorphic DNA probes, and quantitative flow cytometry were performed. Results agreed that an unbalanced fetal complement was present. Southern blot analysis with a 5p marker definitively demonstrated a lack of maternal 5p material in the fetus, and in situ hybridization showed a 5q marker at either end of the recombinant chromosome. Flow cytometry was consistent with this interpretation. Because of the advanced gestational age, the parents elected to terminate based on cytogenic results of the second amniocentesis, rather than to wait another 1-2 weeks for results of other methods.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3228143     DOI: 10.1002/ajmg.1320310320

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  7 in total

1.  Evidence for genetic heterogeneity in tuberous sclerosis: one locus on chromosome 9 and at least one locus elsewhere.

Authors:  H Northrup; D J Kwiatkowski; E S Roach; W B Dobyns; R A Lewis; G E Herman; E Rodriguez; S P Daiger; S H Blanton
Journal:  Am J Hum Genet       Date:  1992-10       Impact factor: 11.025

2.  Homologous and heterologous FISH painting with PARM-PCR chromosome-specific probes in mammals.

Authors:  D Milan; J Riquet; M Yerle; A Goureau; A Schmitz; E P Cribiu; G Frelat; J Gellin
Journal:  Mamm Genome       Date:  1996-03       Impact factor: 2.957

3.  Report of a critical recombination further narrowing the TSC1 region.

Authors:  K S Au; J Murrell; A Buckler; S H Blanton; H Northrup
Journal:  J Med Genet       Date:  1996-07       Impact factor: 6.318

4.  Detection of an unbalanced translocation (4;14) in a mildly retarded father and son by flow cytometry.

Authors:  A Cooke; J L Tolmie; J M Colgan; C M Greig; J M Connor
Journal:  Hum Genet       Date:  1989-08       Impact factor: 4.132

5.  Chromosome heteromorphism quantified by high-resolution bivariate flow karyotyping.

Authors:  B Trask; G van den Engh; B Mayall; J W Gray
Journal:  Am J Hum Genet       Date:  1989-11       Impact factor: 11.025

6.  Molecular analysis of the human vitamin D binding protein (group specific component, Gc) in tuberous sclerosis complex (TSC).

Authors:  J A Rodriguez; R L Evans; S P Daiger; H Northrup
Journal:  J Med Genet       Date:  1997-06       Impact factor: 6.318

7.  Evaluation of candidate genes for familial brachydactyly.

Authors:  J M Mastrobattista; P Dollé; S H Blanton; H Northrup
Journal:  J Med Genet       Date:  1995-11       Impact factor: 6.318

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.